Mathai Mammen

Mathai Mammen, M.D., Ph.D. currently serves as the CEO, President, and Chairman of FogPharma, leading initiatives to develop transformative medicines for patients. Mammen also holds the position of Executive Advisor at General Atlantic and has been a Board Member of 10x Genomics since February 2017, contributing to advancements in single-cell sequencing and spatial genomics. From June 2017 to February 2023, Mammen was the Executive Vice President of Pharmaceuticals R&D at Johnson & Johnson, where significant growth and productivity improvements were achieved. Previous roles include Senior Vice President at Merck, responsible for multiple therapeutic areas, and R&D leadership positions at Theravance Biopharma, Innoviva, and Theravance, which Mammen co-founded following research at Harvard. Mammen holds an MD from Harvard Medical School, a PhD in Chemistry from Harvard University, and a BSc in Chemistry from Dalhousie University.